Medindia

X

Chronic Cough Pipeline 2016 Global Market Review Report

Wednesday, May 25, 2016 Research News J E 4
Advertisement

PUNE, India, May 25, 2016 /PRNewswire/ --

ReportsnReports.com adds "Chronic Cough - Pipeline Review, H1 2016"market research report that provides an overview on therapeutic pipeline of Chronic Cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Cough and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Chronic Cough with 25 market data tables and 12 figures, spread across 60 pages is available at http://www.reportsnreports.com/reports/541475-chronic-cough-pipeline-review-h1-2016.html

The report also reviews key players involved in the therapeutic development for Chronic Cough and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Chronic Cough Pipeline Review, H1 2016 report include Afferent Pharmaceuticals, Inc., Ario Pharma Ltd, AstraZeneca Plc, Conrig Pharma ApS, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., GW Pharmaceuticals Plc, NeRRe Therapeutics Ltd and Patara Pharma, Inc.

Drug Profiles discussed in this research are AF-219, cromolyn sodium, GRC-17536, GRC-17536, lesogaberan, NEO-5937, orvepitant maleate, S-122, Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases, ST-015 and XEND-0501.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Chronic Cough and reviews pipeline therapeutics for Chronic Cough by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Chronic Cough therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Chronic Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Chronic Cough.

Order a copy of Chronic Cough Pipeline Review, H1 2016 report @ http://www.reportsnreports.com/Purchase.aspx?name=541475

Reasons to buy 

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chronic Cough
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chronic Cough pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Another newly published market research report titled on Lipodystrophy - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Lipodystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lipodystrophy and special features on late-stage and discontinued projects. Companies discussed in this research are Aegerion Pharmaceuticals, Inc., Ambrx, Inc., Bolder Biotechnology, Inc., Galmed Pharmaceuticals Ltd., Theratechnologies Inc. and Zydus Cadila Healthcare Limited. Lipodystrophy Pipeline market research report of 63 pages is available athttp://www.reportsnreports.com/reports/531480-lipodystrophy-pipeline-review-h1-2016.html

Explore more reports on Pharmaceuticals     

About Us: 

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more. Connect With Us on:

Facebook:https://www.facebook.com/ReportsnReports/

LinkedIn:https://www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

Contact: Ritesh Tiwari UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune - 411013 Maharashtra, India. +1 888 391 5441 sales@reportsandreports.com

SOURCE ReportsnReports

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Global Respiratory Drugs Market 2016-2020 - Promis...
S
Dr. Pankaj Naram and a New Study; Does High-Fat Fo...